Annual EBITDA
-$30.90 M
+$913.00 K+2.87%
December 31, 2023
Summary
- As of February 7, 2025, TCRT annual EBITDA is -$30.90 million, with the most recent change of +$913.00 thousand (+2.87%) on December 31, 2023.
- During the last 3 years, TCRT annual EBITDA has risen by +$47.94 million (+60.81%).
- TCRT annual EBITDA is now -78938.36% below its all-time high of -$39.10 thousand, reached on December 31, 2002.
Performance
TCRT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$1.13 M
+$1000.00+0.09%
September 30, 2024
Summary
- As of February 7, 2025, TCRT quarterly EBITDA is -$1.13 million, with the most recent change of +$1000.00 (+0.09%) on September 30, 2024.
- Over the past year, TCRT quarterly EBITDA has increased by +$1000.00 (+0.09%).
- TCRT quarterly EBITDA is now -26733.33% below its all-time high of -$4200.00, reached on September 30, 2000.
Performance
TCRT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$11.54 M
+$6.67 M+36.63%
September 30, 2024
Summary
- As of February 7, 2025, TCRT TTM EBITDA is -$11.54 million, with the most recent change of +$6.67 million (+36.63%) on September 30, 2024.
- Over the past year, TCRT TTM EBITDA has increased by +$6.67 million (+36.63%).
- TCRT TTM EBITDA is now -39820.42% below its all-time high of -$28.90 thousand, reached on June 30, 2000.
Performance
TCRT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TCRT EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +2.9% | +0.1% | +36.6% |
| 3 y3 years | +60.8% | +94.8% | +86.7% |
| 5 y5 years | +42.0% | +94.4% | +84.1% |
TCRT EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +58.8% | at high | +89.1% | at high | +84.6% |
| 5 y | 5-year | at high | +60.8% | at high | +94.9% | at high | +86.7% |
| alltime | all time | <-9999.0% | +81.3% | <-9999.0% | +99.1% | <-9999.0% | +93.2% |
Alaunos Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$1.13 M(-0.1%) | -$11.54 M(-36.6%) |
| Jun 2024 | - | -$1.13 M(-32.9%) | -$18.21 M(-24.4%) |
| Mar 2024 | - | -$1.68 M(-77.9%) | -$24.09 M(-22.1%) |
| Dec 2023 | -$30.90 M(-2.9%) | -$7.60 M(-2.5%) | -$30.90 M(+0.1%) |
| Sep 2023 | - | -$7.80 M(+11.3%) | -$30.88 M(+1.6%) |
| Jun 2023 | - | -$7.01 M(-17.6%) | -$30.40 M(-4.7%) |
| Mar 2023 | - | -$8.50 M(+12.2%) | -$31.90 M(+0.3%) |
| Dec 2022 | -$31.82 M(-57.6%) | -$7.58 M(+3.5%) | -$31.82 M(-8.0%) |
| Sep 2022 | - | -$7.32 M(-14.0%) | -$34.59 M(-29.2%) |
| Jun 2022 | - | -$8.51 M(+1.1%) | -$48.88 M(-21.6%) |
| Mar 2022 | - | -$8.42 M(-18.6%) | -$62.37 M(-16.8%) |
| Dec 2021 | -$74.97 M(-4.9%) | -$10.34 M(-52.1%) | -$74.97 M(-13.4%) |
| Sep 2021 | - | -$21.62 M(-1.7%) | -$86.59 M(+1.9%) |
| Jun 2021 | - | -$21.99 M(+4.6%) | -$84.98 M(+4.5%) |
| Mar 2021 | - | -$21.01 M(-4.3%) | -$81.34 M(+3.2%) |
| Dec 2020 | -$78.85 M(+37.8%) | -$21.97 M(+9.8%) | -$78.85 M(+8.4%) |
| Sep 2020 | - | -$20.00 M(+9.0%) | -$72.74 M(+10.2%) |
| Jun 2020 | - | -$18.36 M(-0.9%) | -$66.03 M(+6.0%) |
| Mar 2020 | - | -$18.52 M(+16.8%) | -$62.27 M(+8.8%) |
| Dec 2019 | -$57.23 M(+7.3%) | -$15.86 M(+19.3%) | -$57.23 M(+6.0%) |
| Sep 2019 | - | -$13.29 M(-8.9%) | -$53.97 M(+1.7%) |
| Jun 2019 | - | -$14.60 M(+8.3%) | -$53.09 M(+4.6%) |
| Mar 2019 | - | -$13.48 M(+7.0%) | -$50.73 M(-4.9%) |
| Dec 2018 | -$53.33 M(+0.4%) | -$12.60 M(+1.5%) | -$53.33 M(-1.3%) |
| Sep 2018 | - | -$12.41 M(+1.4%) | -$54.06 M(-1.0%) |
| Jun 2018 | - | -$12.24 M(-23.9%) | -$54.63 M(-1.2%) |
| Mar 2018 | - | -$16.08 M(+20.7%) | -$55.32 M(+4.1%) |
| Dec 2017 | -$53.12 M(-67.8%) | -$13.33 M(+2.6%) | -$53.12 M(+4.5%) |
| Sep 2017 | - | -$12.99 M(+0.5%) | -$50.85 M(+4.4%) |
| Jun 2017 | - | -$12.93 M(-6.9%) | -$48.70 M(-70.8%) |
| Mar 2017 | - | -$13.89 M(+25.7%) | -$166.94 M(+1.2%) |
| Dec 2016 | -$165.02 M(+37.8%) | -$11.05 M(+1.9%) | -$165.02 M(+1.0%) |
| Sep 2016 | - | -$10.84 M(-91.7%) | -$163.39 M(-4.3%) |
| Jun 2016 | - | -$131.16 M(+995.9%) | -$170.65 M(+218.3%) |
| Mar 2016 | - | -$11.97 M(+27.0%) | -$53.61 M(-55.2%) |
| Dec 2015 | -$119.74 M(+178.2%) | -$9.42 M(-48.0%) | -$119.74 M(-0.9%) |
| Sep 2015 | - | -$18.11 M(+28.3%) | -$120.80 M(+5.5%) |
| Jun 2015 | - | -$14.11 M(-81.9%) | -$114.51 M(+2.7%) |
| Mar 2015 | - | -$78.11 M(+645.8%) | -$111.48 M(+159.0%) |
| Dec 2014 | -$43.04 M(-24.5%) | -$10.47 M(-11.4%) | -$43.04 M(+10.0%) |
| Sep 2014 | - | -$11.82 M(+6.6%) | -$39.13 M(+8.0%) |
| Jun 2014 | - | -$11.08 M(+14.7%) | -$36.24 M(-16.2%) |
| Mar 2014 | - | -$9.66 M(+47.1%) | -$43.25 M(-24.1%) |
| Dec 2013 | -$56.98 M(-43.9%) | -$6.57 M(-26.5%) | -$56.98 M(-36.0%) |
| Sep 2013 | - | -$8.93 M(-50.7%) | -$89.06 M(-12.4%) |
| Jun 2013 | - | -$18.10 M(-22.6%) | -$101.66 M(-4.4%) |
| Mar 2013 | - | -$23.38 M(-39.5%) | -$106.38 M(+4.8%) |
| Dec 2012 | -$101.51 M | -$38.65 M(+79.6%) | -$101.51 M(+28.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2012 | - | -$21.53 M(-5.7%) | -$79.18 M(+10.3%) |
| Jun 2012 | - | -$22.82 M(+23.2%) | -$71.79 M(+16.2%) |
| Mar 2012 | - | -$18.52 M(+13.4%) | -$61.76 M(-13.2%) |
| Dec 2011 | -$71.13 M(+192.0%) | -$16.32 M(+15.5%) | -$71.13 M(+16.3%) |
| Sep 2011 | - | -$14.13 M(+10.5%) | -$61.14 M(+10.2%) |
| Jun 2011 | - | -$12.79 M(-54.1%) | -$55.47 M(+16.2%) |
| Mar 2011 | - | -$27.89 M(+340.9%) | -$47.74 M(+96.0%) |
| Dec 2010 | -$24.36 M(+106.5%) | -$6.33 M(-25.3%) | -$24.36 M(+10.8%) |
| Sep 2010 | - | -$8.46 M(+67.0%) | -$21.98 M(+37.3%) |
| Jun 2010 | - | -$5.07 M(+12.5%) | -$16.01 M(+22.7%) |
| Mar 2010 | - | -$4.50 M(+13.9%) | -$13.05 M(+10.6%) |
| Dec 2009 | -$11.79 M(-53.3%) | -$3.95 M(+58.9%) | -$11.79 M(-4.1%) |
| Sep 2009 | - | -$2.49 M(+18.0%) | -$12.30 M(-19.8%) |
| Jun 2009 | - | -$2.11 M(-35.1%) | -$15.34 M(-22.3%) |
| Mar 2009 | - | -$3.25 M(-27.1%) | -$19.75 M(-21.7%) |
| Dec 2008 | -$25.23 M(-10.3%) | -$4.46 M(-19.4%) | -$25.23 M(-12.3%) |
| Sep 2008 | - | -$5.53 M(-15.1%) | -$28.78 M(-7.0%) |
| Jun 2008 | - | -$6.51 M(-25.4%) | -$30.95 M(-1.8%) |
| Mar 2008 | - | -$8.73 M(+9.0%) | -$31.52 M(+12.0%) |
| Dec 2007 | -$28.14 M(+48.6%) | -$8.01 M(+4.0%) | -$28.14 M(+7.0%) |
| Sep 2007 | - | -$7.70 M(+8.7%) | -$26.29 M(+16.9%) |
| Jun 2007 | - | -$7.08 M(+32.4%) | -$22.48 M(+6.8%) |
| Mar 2007 | - | -$5.35 M(-13.2%) | -$21.05 M(+11.1%) |
| Dec 2006 | -$18.94 M(+95.5%) | -$6.16 M(+58.5%) | -$18.94 M(+23.8%) |
| Sep 2006 | - | -$3.89 M(-31.2%) | -$15.30 M(+7.4%) |
| Jun 2006 | - | -$5.65 M(+74.6%) | -$14.24 M(+33.4%) |
| Mar 2006 | - | -$3.24 M(+28.2%) | -$10.68 M(+10.3%) |
| Dec 2005 | -$9.69 M(+70.7%) | -$2.53 M(-10.9%) | -$9.69 M(-1.1%) |
| Sep 2005 | - | -$2.83 M(+35.8%) | -$9.79 M(+17.8%) |
| Jun 2005 | - | -$2.09 M(-6.9%) | -$8.31 M(+33.2%) |
| Mar 2005 | - | -$2.24 M(-14.7%) | -$6.24 M(+55.8%) |
| Dec 2004 | -$5.67 M(+3433.4%) | -$2.63 M(+94.2%) | -$4.00 M(+164.9%) |
| Sep 2004 | - | -$1.35 M(+8255.6%) | -$1.51 M(+805.9%) |
| Jun 2004 | - | -$16.20 K(+145.5%) | -$166.90 K(+6.2%) |
| Mar 2004 | - | -$6600.00(-95.1%) | -$157.10 K(-1.9%) |
| Dec 2003 | -$160.60 K(+310.7%) | -$135.60 K(+1495.3%) | -$160.20 K(+355.1%) |
| Sep 2003 | - | -$8500.00(+32.8%) | -$35.20 K(+6.7%) |
| Jun 2003 | - | -$6400.00(-34.0%) | -$33.00 K(-17.1%) |
| Mar 2003 | - | -$9700.00(-8.5%) | -$39.80 K(+1.8%) |
| Dec 2002 | -$39.10 K(-45.5%) | -$10.60 K(+68.3%) | -$39.10 K(-43.1%) |
| Sep 2002 | - | -$6300.00(-52.3%) | -$68.70 K(-0.6%) |
| Jun 2002 | - | -$13.20 K(+46.7%) | -$69.10 K(+2.4%) |
| Mar 2002 | - | -$9000.00(-77.6%) | -$67.50 K(-5.9%) |
| Dec 2001 | -$71.80 K | -$40.20 K(+500.0%) | -$71.70 K(+127.6%) |
| Sep 2001 | - | -$6700.00(-42.2%) | -$31.50 K(+8.6%) |
| Jun 2001 | - | -$11.60 K(-12.1%) | -$29.00 K(-37.4%) |
| Mar 2001 | - | -$13.20 K(+214.3%) | -$46.30 K(+39.9%) |
| Sep 2000 | - | -$4200.00(-85.5%) | -$33.10 K(+14.5%) |
| Jun 2000 | - | -$28.90 K | -$28.90 K |
FAQ
- What is Alaunos Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Alaunos Therapeutics?
- What is Alaunos Therapeutics annual EBITDA year-on-year change?
- What is Alaunos Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Alaunos Therapeutics?
- What is Alaunos Therapeutics quarterly EBITDA year-on-year change?
- What is Alaunos Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Alaunos Therapeutics?
- What is Alaunos Therapeutics TTM EBITDA year-on-year change?
What is Alaunos Therapeutics annual EBITDA?
The current annual EBITDA of TCRT is -$30.90 M
What is the all time high annual EBITDA for Alaunos Therapeutics?
Alaunos Therapeutics all-time high annual EBITDA is -$39.10 K
What is Alaunos Therapeutics annual EBITDA year-on-year change?
Over the past year, TCRT annual EBITDA has changed by +$913.00 K (+2.87%)
What is Alaunos Therapeutics quarterly EBITDA?
The current quarterly EBITDA of TCRT is -$1.13 M
What is the all time high quarterly EBITDA for Alaunos Therapeutics?
Alaunos Therapeutics all-time high quarterly EBITDA is -$4200.00
What is Alaunos Therapeutics quarterly EBITDA year-on-year change?
Over the past year, TCRT quarterly EBITDA has changed by +$1000.00 (+0.09%)
What is Alaunos Therapeutics TTM EBITDA?
The current TTM EBITDA of TCRT is -$11.54 M
What is the all time high TTM EBITDA for Alaunos Therapeutics?
Alaunos Therapeutics all-time high TTM EBITDA is -$28.90 K
What is Alaunos Therapeutics TTM EBITDA year-on-year change?
Over the past year, TCRT TTM EBITDA has changed by +$6.67 M (+36.63%)